AstraZeneca raised its interim dividend by 3.0% to USD1.03 from USD1.00 a year ago. Revenue for lung cancer drug Imfinzi was up 20%, while sales of breast cancer treatment Enhertu climbed 35% and ...

AstraZeneca's quarterly revenue beat expectations, boosted by its oncology and biopharmaceuticals segments and strong U.S. demand. The Anglo-Swedish pharmaceutical giant said Tuesday that for the ...

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced European pharma tariffs. The company also announced estimate-beating earnings, ...

Trastuzumab deruxtecan-nxki (Enhertu; AstraZeneca, Daiichi Sankyo), commonly known as T-DXd, demonstrated the most efficacy in patients with HER2-positive disease, who had a real-world PFS of 1 year.

As first-line treatments in metastatic HER2-positive breast cancer evolve, the firm expects its HER2-targeted therapies to remain integral to growth.

A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden’s prostate cancer was recently labelled “aggressive” and described ...

AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America’s global leadership in medicines manufacturing and R& ...

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved survival rates for patients.

5 questions on Sarepta, the FDA and a Duchenne gene therapy crisis While Sarepta has now consented to the FDA’s request to stop selling Elevidys, the company’s brief standoff with the agency could ...

Home Investing Wellness Stocks to Invest in Now Breakthroughs that help us live longer, healthier lives can also create opportunities for investors.

Panel urges FDA to remove warnings on hormonal menopause therapy Experts convened by FDA head Martin Makary called on the agency to revise the drugs’ labeling, which has for years cautioned of cancer ...

ENHERTU® Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer ...